Bio-Rad Laboratories (BIO) Stock Forecast, Price Target & Predictions
BIO Stock Forecast
Bio-Rad Laboratories stock forecast is as follows: an average price target of $400.00 (represents a 23.56% upside from BIO’s last price of $323.74) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
BIO Price Target
The average price target for Bio-Rad Laboratories (BIO) is $400.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $400.00. This represents a potential 23.56% upside from BIO's last price of $323.74.
BIO Analyst Ratings
According to 4 Wall Street analysts, Bio-Rad Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for BIO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bio-Rad Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 01, 2024 | Patrick Donnelly | Citigroup | $400.00 | $338.58 | 18.14% | 23.56% |
| Dec 07, 2022 | RBC Capital | $565.00 | $399.59 | 41.39% | 74.53% |
The latest Bio-Rad Laboratories stock forecast, released on Oct 01, 2024 by Patrick Donnelly from Citigroup, set a price target of $400.00, which represents a 18.14% increase from the stock price at the time of the forecast ($338.58), and a 23.56% increase from BIO last price ($323.74).
Bio-Rad Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $400.00 | $400.00 |
| Last Closing Price | $323.74 | $323.74 | $323.74 |
| Upside/Downside | -100.00% | 23.56% | 23.56% |
In the current month, the average price target of Bio-Rad Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bio-Rad Laboratories's last price of $323.74. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 31, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 01, 2024 | Citigroup | Neutral | Buy | Upgrade |
| Aug 27, 2024 | Wells Fargo | Equal-Weight | Initialise | |
| Jun 03, 2024 | Jefferies | Hold | Downgrade | |
| Apr 03, 2024 | Citigroup | Neutral | Downgrade | |
| Dec 07, 2022 | RBC Capital | Outperform | Initialise |
Bio-Rad Laboratories's last stock rating was published by RBC Capital on Oct 31, 2024. The company gave BIO a "Outperform" rating, the same as its previous rate.
Bio-Rad Laboratories Financial Forecast
Bio-Rad Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $2.67T | $632.12M | $681.11M | $676.84M | $730.29M | $680.80M | $691.10M | $700.06M | $732.77M | $747.05M | $715.93M | $726.80M | $789.84M | $647.26M | $536.88M | $571.64M | $624.43M | $560.63M |
| Avg Forecast | $726.05M | $688.94M | $676.60M | $643.79M | $703.18M | $670.85M | $658.34M | $622.84M | $679.99M | $628.18M | $645.79M | $619.09M | $685.00M | $689.50M | $697.96M | $689.96M | $742.26M | $679.94M | $682.62M | $672.63M | $730.26M | $664.57M | $646.07M | $660.98M | $686.79M | $570.57M | $517.06M | $546.85M | $641.46M | $561.40M |
| High Forecast | $729.73M | $692.43M | $680.03M | $647.05M | $706.75M | $674.25M | $661.68M | $623.81M | $681.88M | $628.91M | $645.79M | $619.09M | $685.01M | $692.76M | $701.50M | $693.46M | $746.02M | $679.94M | $682.62M | $672.63M | $730.26M | $664.57M | $646.07M | $660.98M | $686.79M | $570.57M | $517.06M | $546.85M | $641.46M | $561.40M |
| Low Forecast | $722.04M | $685.13M | $672.86M | $640.23M | $699.29M | $667.14M | $654.70M | $621.88M | $678.10M | $627.44M | $645.79M | $619.09M | $684.99M | $683.17M | $694.10M | $686.15M | $738.15M | $679.94M | $682.62M | $672.63M | $730.26M | $664.57M | $646.07M | $660.98M | $686.79M | $570.57M | $517.06M | $546.85M | $641.46M | $561.40M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 9 | 6 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3896.77% | 0.92% | 0.98% | 0.98% | 0.98% | 1.00% | 1.01% | 1.04% | 1.00% | 1.12% | 1.11% | 1.10% | 1.15% | 1.13% | 1.04% | 1.05% | 0.97% | 1.00% |
Bio-Rad Laboratories's average Quarter revenue forecast for Mar 24 based on 1 analysts is $619.09M, with a low forecast of $619.09M, and a high forecast of $619.09M. BIO's average Quarter revenue forecast represents a -99.98% decrease compared to the company's last Quarter revenue of $2.67T (Dec 23).
Bio-Rad Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 9 | 6 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-373.97B | $90.95M | $89.62M | $147.93M | $160.83M | $128.58M | $159.54M | $208.03M | $-2.00B | $5.06B | $1.19B | $1.33B | $1.12B | $1.72B | $1.29B | $937.99M | $708.79M | $-284.69M |
| Avg Forecast | $257.36M | $244.20M | $239.83M | $228.20M | $249.25M | $237.79M | $233.35M | $220.77M | $241.03M | $222.66M | $228.91M | $-1.70B | $242.80M | $244.40M | $247.40M | $-1.54B | $-1.94B | $145.41M | $145.98M | $-1.40B | $156.17M | $142.12M | $138.16M | $141.35M | $146.87M | $122.02M | $110.57M | $116.95M | $137.18M | $120.06M |
| High Forecast | $258.66M | $245.44M | $241.04M | $229.35M | $250.51M | $238.99M | $234.54M | $221.11M | $241.70M | $222.92M | $228.91M | $-1.36B | $242.81M | $245.56M | $248.65M | $-1.23B | $-1.55B | $145.41M | $145.98M | $-1.12B | $156.17M | $142.12M | $138.16M | $141.35M | $146.87M | $122.02M | $110.57M | $116.95M | $137.18M | $120.06M |
| Low Forecast | $255.93M | $242.85M | $238.50M | $226.94M | $247.87M | $236.47M | $232.06M | $220.43M | $240.36M | $222.40M | $228.91M | $-2.04B | $242.80M | $242.16M | $246.03M | $-1.85B | $-2.33B | $145.41M | $145.98M | $-1.68B | $156.17M | $142.12M | $138.16M | $141.35M | $146.87M | $122.02M | $110.57M | $116.95M | $137.18M | $120.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1540.23% | 0.37% | 0.36% | -0.10% | -0.08% | 0.88% | 1.09% | -0.15% | -12.83% | 35.58% | 8.62% | 9.41% | 7.62% | 14.13% | 11.63% | 8.02% | 5.17% | -2.37% |
2 analysts predict BIO's average Quarter EBITDA for Dec 23 to be $242.80M, with a high of $242.81M and a low of $242.80M. This is 166.97% upper than Bio-Rad Laboratories's previous annual EBITDA (Sep 23) of $90.95M.
Bio-Rad Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 9 | 6 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-636.34B | $106.26M | $-1.16B | $68.96M | $827.73M | $-164.23M | $-927.18M | $-3.37B | $-1.57B | $3.93B | $914.11M | $977.41M | $839.10M | $1.31B | $966.43M | $685.91M | $553.49M | $-258.82M |
| Avg Forecast | $100.13M | $91.90M | $85.79M | $78.72M | $85.30M | $81.56M | $80.79M | $74.32M | $80.32M | $32.38M | $56.38M | $-2.45B | $78.87M | $77.86M | $74.97M | $-2.23B | $-1.53B | $79.00M | $79.47M | $-2.03B | $80.94M | $69.21M | $75.66M | $955.04M | $93.56M | $51.18M | $34.74M | $537.37M | $69.43M | $39.89M |
| High Forecast | $100.79M | $92.50M | $86.36M | $79.24M | $85.86M | $82.10M | $81.32M | $75.28M | $83.11M | $32.60M | $56.38M | $-1.96B | $79.39M | $81.78M | $75.47M | $-1.78B | $-1.22B | $79.00M | $79.47M | $-1.62B | $80.94M | $69.21M | $75.66M | $1.15B | $93.56M | $51.18M | $34.74M | $644.84M | $69.43M | $39.89M |
| Low Forecast | $99.41M | $91.24M | $85.18M | $78.16M | $84.68M | $80.98M | $80.21M | $73.35M | $77.25M | $32.15M | $56.37M | $-2.94B | $78.60M | $73.38M | $74.43M | $-2.68B | $-1.83B | $79.00M | $79.47M | $-2.43B | $80.94M | $69.21M | $75.66M | $764.04M | $93.56M | $51.18M | $34.74M | $429.90M | $69.43M | $39.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -8068.62% | 1.36% | -15.50% | -0.03% | -0.54% | -2.08% | -11.67% | 1.66% | -19.44% | 56.76% | 12.08% | 1.02% | 8.97% | 25.69% | 27.82% | 1.28% | 7.97% | -6.49% |
Bio-Rad Laboratories's average Quarter net income forecast for Dec 23 is $78.87M, with a range of $78.60M to $79.39M. BIO's average Quarter net income forecast represents a -25.78% decrease compared to the company's last Quarter net income of $106.26M (Sep 23).
Bio-Rad Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 9 | 6 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $841.09B | $201.20M | $207.82M | $225.55M | $212.23M | $211.05M | $208.73M | $197.59M | $224.15M | $216.15M | $213.43M | $225.85M | $219.15M | $198.16M | $189.26M | $193.69M | $214.16M | $201.62M |
| Avg Forecast | $228.66M | $216.97M | $213.08M | $202.75M | $221.46M | $211.27M | $207.33M | $196.15M | $214.15M | $197.84M | $203.38M | $143.88M | $215.73M | $217.15M | $219.81M | $130.80M | $217.35M | $214.14M | $214.98M | $118.91M | $229.99M | $209.30M | $203.47M | $220.68M | $216.29M | $179.69M | $162.84M | $151.75M | $202.02M | $176.80M |
| High Forecast | $229.82M | $218.07M | $214.16M | $203.78M | $222.58M | $212.34M | $208.38M | $196.46M | $214.75M | $198.07M | $203.38M | $172.65M | $215.73M | $218.18M | $220.93M | $156.95M | $260.82M | $214.14M | $214.98M | $142.69M | $229.99M | $209.30M | $203.47M | $264.82M | $216.29M | $179.69M | $162.84M | $182.10M | $202.02M | $176.80M |
| Low Forecast | $227.40M | $215.77M | $211.91M | $201.63M | $220.23M | $210.11M | $206.19M | $195.85M | $213.56M | $197.60M | $203.38M | $115.10M | $215.73M | $215.16M | $218.60M | $104.64M | $173.88M | $214.14M | $214.98M | $95.12M | $229.99M | $209.30M | $203.47M | $176.55M | $216.29M | $179.69M | $162.84M | $121.40M | $202.02M | $176.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3898.81% | 0.93% | 0.95% | 1.72% | 0.98% | 0.99% | 0.97% | 1.66% | 0.97% | 1.03% | 1.05% | 1.02% | 1.01% | 1.10% | 1.16% | 1.28% | 1.06% | 1.14% |
Bio-Rad Laboratories's average Quarter SG&A projection for Mar 24 is $143.88M, based on 1 Wall Street analysts, with a range of $115.10M to $172.65M. The forecast indicates a -99.98% fall compared to BIO last annual SG&A of $841.09B (Dec 23).
Bio-Rad Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 5 | 9 | 6 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-21.79 | $3.65 | $-39.59 | $2.33 | $27.89 | $-5.52 | $-31.12 | $-112.57 | $-52.59 | $131.75 | $30.71 | $32.77 | $28.13 | $44.24 | $32.59 | $22.97 | $18.50 | $-8.68 |
| Avg Forecast | $3.58 | $3.28 | $3.07 | $2.81 | $3.05 | $2.91 | $2.89 | $2.66 | $2.87 | $1.16 | $2.01 | $2.15 | $2.82 | $2.78 | $2.68 | $3.54 | $3.45 | $2.78 | $2.80 | $3.37 | $2.85 | $2.44 | $2.66 | $2.99 | $3.29 | $1.80 | $1.22 | $1.57 | $2.45 | $1.41 |
| High Forecast | $3.60 | $3.31 | $3.09 | $2.83 | $3.07 | $2.93 | $2.91 | $2.69 | $2.97 | $1.16 | $2.01 | $2.15 | $2.84 | $2.92 | $2.70 | $3.57 | $3.47 | $2.78 | $2.80 | $3.37 | $2.85 | $2.44 | $2.66 | $2.99 | $3.29 | $1.80 | $1.22 | $1.57 | $2.45 | $1.41 |
| Low Forecast | $3.55 | $3.26 | $3.04 | $2.79 | $3.03 | $2.89 | $2.87 | $2.62 | $2.76 | $1.15 | $2.01 | $2.15 | $2.81 | $2.62 | $2.66 | $3.52 | $3.42 | $2.78 | $2.80 | $3.37 | $2.85 | $2.44 | $2.66 | $2.99 | $3.29 | $1.80 | $1.22 | $1.57 | $2.45 | $1.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -7.73% | 1.31% | -14.78% | 0.66% | 8.09% | -1.98% | -11.12% | -33.41% | -18.45% | 54.06% | 11.53% | 10.94% | 8.54% | 24.55% | 26.64% | 14.68% | 7.57% | -6.18% |
According to 2 Wall Street analysts, Bio-Rad Laboratories's projected average Quarter EPS for Dec 23 is $2.82, with a low estimate of $2.81 and a high estimate of $2.84. This represents a -22.79% decrease compared to BIO previous annual EPS of $3.65 (Sep 23).
Bio-Rad Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care | $34.23 | $51.43 | 50.25% | Buy |
| BRKR | Bruker | $57.81 | $79.00 | 36.65% | Buy |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| DXCM | DexCom | $77.80 | $104.50 | 34.32% | Buy |
| STE | STERIS | $209.51 | $262.50 | 25.29% | Buy |
| BIO | Bio-Rad Laboratories | $337.85 | $400.00 | 18.40% | Buy |
| INSP | Inspire Medical Systems | $190.71 | $223.17 | 17.02% | Buy |
| NARI | Inari Medical | $56.16 | $64.00 | 13.96% | Buy |
| ZBH | Zimmer Biomet | $108.06 | $121.78 | 12.70% | Hold |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| GMED | Globus Medical | $83.42 | $85.00 | 1.89% | Buy |
| PODD | Insulet | $263.35 | $268.00 | 1.77% | Buy |
| GKOS | Glaukos | $146.35 | $144.14 | -1.51% | Buy |
| NVCR | NovoCure | $32.10 | $30.00 | -6.54% | Hold |
| PEN | Penumbra | $247.55 | $230.25 | -6.99% | Buy |